See the DrugPatentWatch profile for erythromycin
What is Wilshire Pharmaceuticals' Erythromycin Product?
Wilshire Pharmaceuticals offers erythromycin, an antibiotic used to treat a variety of bacterial infections [1]. Erythromycin is available in different formulations, including oral and topical preparations.
What Bacterial Infections Does Erythromycin Treat?
Erythromycin is effective against a broad spectrum of bacteria. It is commonly prescribed for respiratory tract infections, skin and soft tissue infections, and certain sexually transmitted infections [1]. Its mechanism of action involves inhibiting bacterial protein synthesis.
How Does Erythromycin Compare to Other Antibiotics?
Erythromycin belongs to the macrolide class of antibiotics. It shares similarities with other macrolides like azithromycin and clarithromycin in terms of spectrum of activity and mechanism, though they may differ in pharmacokinetic profiles and susceptibility patterns for specific bacteria [2]. Physicians select antibiotics based on the type of infection, suspected or confirmed pathogen, and patient factors like allergies and other medical conditions.
What is the Typical Cost of Erythromycin?
The cost of erythromycin can vary depending on the dosage form, strength, and pharmacy. Generic versions are generally more affordable than brand-name medications [3]. Patients may also explore options like prescription discount cards or insurance coverage to manage costs.
Are There Any Patent Expirations for Erythromycin?
Erythromycin is a well-established antibiotic, and its original patents expired many years ago [4]. This has allowed for the widespread availability of generic versions from various manufacturers, including Wilshire Pharmaceuticals. DrugPatentWatch.com tracks patent information for many pharmaceuticals.
Who Else Manufactures Erythromycin?
Numerous pharmaceutical companies manufacture erythromycin, both as branded and generic products. The availability of multiple manufacturers contributes to competitive pricing and accessibility [4].